300871 WuHan Hvsen Biotechnology
- 15.30
- -0.15-0.97%
WuHan Hvsen Biotechnology News
Huisheng Biology (300871.SZ): Mainly engaged in R&D, production and sales of veterinary chemical preparations, raw materials and traditional Chinese medicine preparations, feed and additives
Gelonghui, May 8, 丨 Huisheng Biotech (300871.SZ) said on the investor interactive platform that the company is mainly engaged in R&D, production and sales of veterinary chemical preparations, APIs and traditional Chinese medicine preparations, feed and additives.
Huisheng Biotech (300871): Multiple factors influence short-term performance under pressure, and the recovery in farming sentiment drives a sharp rise in business volume and price
Performance summary: In 2023, the company achieved operating income of 1.02 billion yuan, a year-on-year increase of -0.3%, net profit to mother of 16.78 million yuan, a decrease of 68% year-on-year, and net profit after deduction of -1,119 yuan, a year-on-year decrease of 125 yuan
Huisheng Biotech (300871): Short-term performance is clearly under pressure due to multiple factors such as sluggish downstream demand and credit impairment accruals
Short-term performance is clearly under pressure due to multiple factors such as sluggish downstream demand and credit impairment accruals. The company achieved operating income of 1,020 billion yuan in 2023, -0.31% year-on-year, mainly due to downstream aquaculture losses and financial constraints
Minsheng Securities released a research report on April 25 stating that Huisheng Biotech (300871.SZ) was given a recommended rating. The main reasons for the rating include: 1) the slump in the farming market affects the company's performance, and the low
Minsheng Securities released a research report on April 25 stating that Huisheng Biotech (300871.SZ) was given a recommended rating. The main reasons for the rating include: 1) the slump in the farming market affects the company's performance, and the low utilization rate of new construction projects raises initial costs; 2) fixed increases send a positive signal, demonstrating the confidence of actual controllers in future development; 3) putting effort into R&D and innovation, and completing the production capacity layout for core raw materials. (Mainichi Keizai Shimbun)
Huisheng Biotech (300871.SZ) announced first-quarter results, changing profit to loss to RMB 16.4056 million
Huisheng Biotech (300871.SZ) released its report for the first quarter of 2024. The company's revenue was 2.07...
Express News | Huisheng Biotech: Net profit attributable to shareholders of listed companies in 2023 was 19.5 million yuan to 25 million yuan, down 52.57% to 63.00% from the same period last year.
Huisheng Biotech (300871.SZ): Net profit is expected to drop 52.57% to 63% year-on-year in 2023
On April 10, Gelonghui | Huisheng Biotech (300871.SZ) announced that it expects net profit of 19.5 million yuan to 25 million yuan in 2023, down 52.57% to 63% from the same period last year, after deducting non-net loss of 8.5 million yuan to 13 million yuan. In the early stages, the company did not accrue individual credit impairment losses on accounts receivable from individual customers based on a comprehensive assessment of factors such as customer repayment conditions, financial changes, and development trends in the pig breeding industry. Due to the company's recent acquisition of new information, the customer showed signs of business risk and intended to apply to the court for restructuring and pre-restructuring
Huisheng Biotech (300871) Company Review Report: The fixed increase plan highlights the company's confidence in development, the farming boom, and the company's priority benefits
Incident: On April 3, 2024, the company announced a plan to issue A shares to specific targets in 2024. The target of this fixed increase issuance is Chu Sheng Investment. The total amount of capital to be raised will not exceed RMB 250 million, after deducting the issuance fee
Express News | Huisheng Biotech: Plans to raise no more than 250 million yuan in capital from related parties
Huisheng Biotech (300871.SZ): 2023 Employee Stock Ownership Plan Non-transactional Transfer Completed
Gelonghui, Feb. 8, 丨 Huisheng Biotech (300871.SZ) announced that on February 7, 2024, the company received a “Securities Transfer Registration Confirmation” issued by the Shenzhen branch of China Securities Registration and Settlement Co., Ltd., and 1,635,450 shares of the company's shares held by the “Wuhan Huisheng Biotechnology Co., Ltd. Repurchase Special Securities Account” were transferred to “Wuhan Huisheng Biotechnology Co., Ltd. - 2023 Employee Stock Ownership Plan” on February 6, 2024. The number of shares transferred accounts for 0.99% of the company's total share capital. 10.00 yuan/share. All companies
Huisheng Biotech (300871.SZ): Proposed 2023 employee shareholding plan, the total amount raised will not exceed 167.385 million yuan
Gelonghui, December 27丨Huisheng Biotech (300871.SZ) announced the 2023 employee shareholding plan (draft). The total amount of capital to be raised in the employee shareholding plan is not more than RMB 16.7385 million. Using “shares” as the subscription unit, each share is 1.00 yuan. The maximum number of shares in the employee shareholding plan is 16.7385 million shares. After review and approval by the company's shareholders' meeting, the employee's shareholding plan will use 10 yuan/share to repurchase the shares already repurchased by the company's special securities account. The participants in this employee stock ownership plan are company directors (excluding independent directors), supervisors, and senior management.
Huisheng Biology (300871.SZ): The tylosin project with an annual output of 1,000 tons, the tylosin production line expansion project with an annual output of 1,000 tons, and the tyomycin production line expansion project with an annual output of 600 tons
Glonghui October 30 | Huisheng Biotech (300871.SZ) held an investor relations event on October 29, 2023, on “How is the company's raw material project progressing?” The company replied that the company's tylosin project with an annual output of 1,000 tons, an annual tylosin production line expansion project with an annual output of 1,000 tons, and a tyomycin production line expansion project with an annual output of 600 tons have been fully completed and put into operation. Currently, through continuous optimization of strains and process improvements, tylosin production costs are gradually trending towards the industry average. As capacity utilization increases to create scale effects and further optimization of strains and processes, API projects are imminent
Huisheng Biotech (300871.SZ): Fund-raising projects have been completed and put into operation one after another and are in a climbing phase
Glonghui, Oct. 19丨Some investors asked Huisheng Biotech (300871.SZ) on the investor interactive platform. “What was the production capacity situation in the third quarter?” The company said that the company's fund-raising projects have been completed and put into operation one after another and are in a climbing period.
Huisheng Biotech (300871.SZ): The ban on 82.8 million restricted shares was lifted on September 26
Glonghui September 24, September 24丨Huisheng Biotech (300871.SZ) issued an indicative announcement on the listing and circulation of shares already issued before the initial public offering. The company's shares that have now been lifted from sale restrictions are some of the shares already issued before the company's initial public offering. The number of shares that have been lifted this time is 82.8 million shares, accounting for 49.9134% of the company's total share capital. The current listing and circulation date of restricted shares is September 26, 2023 (Tuesday).
Huisheng Biotech (300871.SZ): Does not revise the “Huisheng Convertible Bonds” stock conversion price downward
Glonghui September 13 | Huisheng Biotech (300871.SZ) announced that as of September 13, 2023, the stock price of Wuhan Huisheng Biotechnology Co., Ltd. from August 24, 2023 to September 13, 2023, had a situation where the closing price for at least 15 out of 30 consecutive trading days was lower than 85% of the conversion price, triggering a downward revision of the “Huisheng Bonds” conversion price. Following deliberation and approval at the sixth meeting of the third board of directors of the company, the board of directors of the company decided not to revise the share conversion price downward at this time, and within six months from the next trading day of review and approval by the board of directors (2
Huisheng Biotech (300871): Revenue growth is steady and the API sector is relatively sluggish
Incident: The company achieved revenue of 449 million yuan in 2023H1, an increase of 13.1% over the previous year, and net profit of 15.9 million yuan, an increase of 144.1% over the previous year; in a single quarter, 2023Q2 achieved revenue of 2.1 million yuan
Huisheng Biology (300871): Pharmaceutical business volume and profit improved +144% year-on-year in the first half of the year
The volume and profit of the formulation business improved, and the year-on-year performance rebounded markedly. The company achieved revenue of 449 million yuan in 2023H1, an increase of 13.11% over the same period last year. It is mainly due to the fact that production capacity in the API sector began to be released; it became owned by the parent company
Huisheng Biotech (300871.SZ) released first-half results, net profit of 158.9979 million yuan, an increase of 144.11%
Huisheng Biotech (300871.SZ) released the 2023 semi-annual report. The company's revenue was 449 million...
Huisheng Biotech (300871.SZ): 2022 Equity Distribution 10 Distribution 3 Yuan Equity Registration Date: June 20
Glonghui, June 14, 丨 Huisheng Biotech (300871.SZ) announced that the company's 2022 equity distribution plan is to distribute RMB 30,000 (tax included) to all shareholders for every 10 shares based on the company's current total share capital of 163,498,105 shares after excluding 2,389,050 shares that have been repurchased. The registration date for this equity distribution is June 20, 2023, and the deduction date is June 21, 2023.
Huisheng Biotech (300871.SZ): The basic construction of the “1000 tons/year tylosin production line expansion project with an annual output of 1,000 tons of tylosin and 600 tons of taivanecin production line” completed
Glonghui, May 26 丨 Huisheng Biotech (300871.SZ) participated in the 2023 Hubei Listed Company Investor Online Group Reception Day at 14:30-16:35 on May 25, 2023, and asked, “Is your company now using Tylomycin produced by your own company to produce Taiwan?” The company replied that the company's “1,000 tons/year tylosin project” has been successfully put into operation, and the infrastructure construction of the “1000 tons/year tylosin production line expansion project with an annual output of 1,000 tons of tylosin and an annual output of 600 tons of taivamectin” has been completed. Currently, the company uses its own tylosin to produce Taiwan.
Analysis
Price Target
No Data
